although a lack of comparative controlled trials make it difficult to determine its relative efficacy to NAC in humans (Buckley 2007)
Emerson, M.D., Ph.D., Sille Esbjerg, M.Sc., Sren HardtLindberg, M.D., Ph.D., G
doi: 10.1016/j.cocis.2020.101413 98 GhezziP
Type 2 diabetes mellitus: a review of multi-target drugs
If GLP-1 receptor agonists reduce migraine burden indirectly while simultaneously improving obesity-related comorbidities such as sleep apnea, hypertension, insulin resistance, and systemic inflammation, some patients may experience broad neurologic and metabolic benefits simultaneously, she added